A phase III study comparing single-agent olaparib or the combination of cediranib and olaparib to standard platinum-based chemotherapy in recurrent platinum-sensitive ovarian cancer

 

Abstract No : 6003

Abstract Type : Oral Abstract Session

Indication : Ovarian

Intervention : Olaparib + Cediranib

Company : U.S. National Institutes of Health

Technology : PARP inhibitor

 

 

Conclusion:

C+O demonstrated similar activity to SOC in relapsed plat-sensitive ovca but did not meet the primary endpoint of improved PFS

 

Commentary:

A rare failure of Olaparib brought a lot of disappointment for ovarian cancer patient community